| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/CLPT.2009.181 |
| P8608 | Fatcat ID | release_imuzwjrgejhhhfsyii4h4mkms4 |
| P698 | PubMed publication ID | 19794410 |
| P50 | author | Pertti J. Neuvonen | Q23039874 |
| Mikko Niemi | Q42328966 | ||
| Ute Hofmann | Q56433692 | ||
| P2093 | author name string | K Klein | |
| M Schwab | |||
| U M Zanger | |||
| J E Keskitalo | |||
| S Riedmaier | |||
| P2860 | cites work | Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy | Q28265991 |
| SLCO1B1 variants and statin-induced myopathy--a genomewide study | Q29619028 | ||
| Achievement of English National Service Framework lipid-lowering goals: pooled data from recent comparative treatment trials of statins at starting doses. | Q31006609 | ||
| Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation | Q33431427 | ||
| Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome | Q34374626 | ||
| Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily | Q34448366 | ||
| Statin-related adverse events: a meta-analysis | Q34496290 | ||
| Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy | Q34536592 | ||
| Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors | Q34556386 | ||
| Statin safety: a systematic review | Q34566154 | ||
| Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance | Q34592657 | ||
| Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population | Q34940968 | ||
| Coordinate regulation of drug metabolism by xenobiotic nuclear receptors: UGTs acting together with CYPs and glucuronide transporters | Q35956173 | ||
| Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes | Q36102590 | ||
| Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions | Q36484039 | ||
| Lipid-activated transcription factors control bile acid glucuronidation | Q37364542 | ||
| Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins | Q39993297 | ||
| Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases | Q40100454 | ||
| Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro | Q40121094 | ||
| A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3. | Q40122180 | ||
| N-glycosylation and residue 96 are involved in the functional properties of UDP-glucuronosyltransferase enzymes | Q40854251 | ||
| Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization | Q43957689 | ||
| Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity | Q44778049 | ||
| ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. | Q45993642 | ||
| Variation in glucuronidation of lamotrigine in human liver microsomes. | Q46039877 | ||
| ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. | Q46111557 | ||
| Acyl-coenzyme a formation of simvastatin in mouse liver preparations | Q46776040 | ||
| Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans | Q46972262 | ||
| Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism | Q46980000 | ||
| Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin | Q57825140 | ||
| SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid | Q57825144 | ||
| Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver | Q60787038 | ||
| The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981 | Q72685071 | ||
| Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid | Q80241790 | ||
| Use of fully denaturing HPLC for UGT1A1 genotyping in Gilbert syndrome | Q81391641 | ||
| Genetic variants of human UGT1A3: functional characterization and frequency distribution in a Chinese Han population | Q83886213 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 65-73 | |
| P577 | publication date | 2009-09-30 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo | |
| P478 | volume | 87 |
| Q90020619 | A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites |
| Q35917726 | A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers. |
| Q39669361 | A simple model predicts UGT-mediated metabolism. |
| Q33891588 | A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes |
| Q36050960 | ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population |
| Q39721147 | Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy |
| Q34921957 | Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor |
| Q49903283 | Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics. |
| Q90756864 | Computational Prediction of Site of Metabolism for UGT-Catalyzed Reactions |
| Q38874222 | Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. |
| Q42917105 | Development of a Population Pharmacokinetic Model for Atorvastatin Acid and Its Lactone Metabolite |
| Q84548365 | Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes |
| Q34570918 | Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer |
| Q39474573 | Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor |
| Q57500258 | Effects ofGinkgo bilobaextracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices |
| Q38707798 | Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis |
| Q50054110 | Genetic variation in statin intolerance and a possible protective role for UGT1A1. |
| Q42714050 | Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting |
| Q37997047 | Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism |
| Q57148214 | Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3 |
| Q35915932 | Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions |
| Q46397769 | Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients |
| Q92177866 | Long-Acting Injectable Statins-Is It Time for a Paradigm Shift? |
| Q34348337 | Mapping genes that predict treatment outcome in admixed populations |
| Q35138221 | Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis |
| Q28068014 | Pediatric Statin Administration: Navigating a Frontier with Limited Data |
| Q38049379 | Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children |
| Q24562836 | PharmGKB summary: very important pharmacogene information for UGT1A1 |
| Q38780996 | Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine? |
| Q93098892 | Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion |
| Q39865051 | Role of pharmacogenetics on deferasirox AUC and efficacy. |
| Q28550067 | Simvastatin Sodium Salt and Fluvastatin Interact with Human Gap Junction Gamma-3 Protein |
| Q57684555 | Solute Carrier (SLC) Family Transporters |
| Q92156926 | Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components |
| Q35478918 | The emerging role of electronic medical records in pharmacogenomics |
| Q36925256 | The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin |
| Q37979858 | The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury |
| Q38188290 | Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. |
| Q86582913 | UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone |
| Q96127313 | UGT1A3 and sex are major determinants of telmisartan pharmacokinetics - a comprehensive pharmacogenomic study |
| Q112978852 | UGT1A3 lactonizes 2-OH-ATV to 2-OH-ATVL |
| Q112978850 | UGT1A3 lactonizes 4-OH-ATV to 4-OH-ATVL |
| Q112978845 | UGT1A3 lactonizes ATV to ATVL |
Search more.